Targeting insulin-like growth factor-1 to treat Alzheimer's disease
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
The 'amyloid cascade hypothesis' proposes that disturbances in amyloid metabolism cause Alzheimer's disease (AD). However, a comprehensive explanation of the mechanisms leading to brain amyloidosis is still pending. Building on previous findings with insulin, and recent observations with insulin-like growth factor-1 (IGF-1) in AD pathology, new evidence suggests that the interaction of environmental factors and inheritance lead to abnormally reduced input/traffic of serum IGF-1 at the blood-brain barriers. The resultant deterioration in brain IGF-1 function may originate all the pathological changes observed in late-onset AD. These include cognitive loss, abnormal amyloid metabolism and aberrant Tau phosphorylation, as well as disturbances, such as inflammation, oxidative stress or mitochondrial dysfunction, among others. A better understanding of the role of IGF-1 in all these perturbations is required, particularly in relation to cognition. Furthermore, insight into the environmental factors contributing to abnormally reduced IGF-1 function in AD brains may become crucial in development of much needed disease-modifying strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice
Holzenberger, M., Dupont, J., Ducos, B., Leneuve, P., Géloën, A., Even, P. C., Cervera, P., & Le Bouc, Y. (2003) · Nature · doi:10.1038/nature01298 · Cited by 2,109 · cited 1×
“However, whether IGF-1 is detrimental or beneficial to organismal longevity in mammals is confounded by seemingly opposing observations of extended or reduced lifespan in mice with low IGF-1 function [26,60-62] .”
BackgroundHydrogen peroxide mediates amyloid β protein toxicity
Behl, C. (1994) · Cell · doi:10.1016/0092-8674(94)90131-7 · Cited by 2,074 · cited 1×
“Oxidative stress is considered the executor of A β neurotoxicity [51] and maladaptive inflammation a consequence of progressive cell damage [52] .”
BackgroundReducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892 · cited 1×
“In particular, the ‘amyloid cascade hypothesis’, which states that the cause of Alzheimer’s disease (AD) stems from the abnormal accumulation of amyloid peptides, although with constant refinements [3] , is taken as the ‘gold standard’ in the field [4] .”
BackgroundSteen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 1×
“This possibility became better acknowledged through the continued effort of several groups documenting an association of insulin with AD [88-92] and with recent observations linking IGF-1 signalling with AD [44] .”
BackgroundThe common biology of cancer and ageing
Finkel, T., Serrano, M., & Blasco, M. A. (2007) · Nature · doi:10.1038/nature05985 · Cited by 988 · cited 1×
“As recently discussed, the involvement of IGF-1 in mammalian ageing is probably related to its, as yet unclear role in pathways controlling the DNA damage response [63] .”
BackgroundMacroautophagy—a novel β-amyloid peptide-generating pathway activated in Alzheimer's disease
Yu, W. H., Cuervo, A. M., Kumar, A., Peterhoff, C. M., Schmidt, S. D., Lee, J.-H., Mohan, P. S., Mercken, M., Farmery, M. R., Tjernberg, L. O., et al. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200505082 · Cited by 967 · cited 1×
“Although the role of IGF-1 signalling through Akt/mTOR on autophagy pathways is cell context dependent [78,79] , it is plausible that disrupted IGF-1 input underlies early autophagic disturbances associated to AD pathology [80,81] .”
BackgroundIncreased Risk of Type 2 Diabetes in Alzheimer Disease
Janson, J., Laedtke, T., Parisi, J. E., O’Brien, P., Petersen, R. C., & Butler, P. C. (2004) · Diabetes · doi:10.2337/diabetes.53.2.474 · Cited by 950 · cited 1×
“Targets (2007) 11(12) Over time, experimental evidence gathered by several groups confirmed that glucose metabolism is altered in AD patients and that diabetic patients may have a greater risk of AD [9,10] .”
BackgroundBrain insulin and insulin receptors in aging and sporadic Alzheimer’s disease
Frölich, L., Blum-Degen, D., Bernstein, H.-G., Engelsberger, S., Humrich, J., Laufer, S., Muschner, D., Thalheimer, A., Türk, A., Hoyer, S., et al. (1998) · Journal of Neural Transmission · doi:10.1007/s007020050068 · Cited by 748 · cited 1×
“This possibility became better acknowledged through the continued effort of several groups documenting an association of insulin with AD [88-92] and with recent observations linking IGF-1 signalling with AD [44] .”
BackgroundMolecular pathways to neurodegeneration
Bossy-Wetzel, E., Schwarzenbacher, R., & Lipton, S. A. (2004) · Nature Medicine · doi:10.1038/nm1067 · Cited by 740 · cited 1×
“Other disturbances that have been linked to AD, albeit with less certainty of their pathogenic significance, include excitotoxicity, autophagy, mitochondrial dysfunction, dysregulation of the unfolded protein response or impaired neurogenesis [75] .”
Background
Cited by
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
Eldar-Finkelman, H., & Martinez, A. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00032 · Cited by 354
Bosco, D., Fava, A., Plastino, M., Montalcini, T., & Pujia, A. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01318.x · Cited by 283
Human conditions of insulin-like growth factor-I (IGF-I) deficiency
Puche, J. E., & Castilla-Cortázar, I. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-224 · Cited by 268
Duman, C. H., Schlesinger, L., Terwilliger, R., Russell, D. S., Newton, S. S., & Duman, R. S. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.11.016 · Cited by 123
“The therapeutic use of IGF-I in neurodegenerative disease has also received attention [16,45,51].”
BackgroundLarouche, E., Hudon, C., & Goulet, S. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.05.058 · Cited by 93
Metadata
- Authors
- Torres-Aleman, I.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa Healthcare
- Published
- 2007-11-18
- Volume
- 11
- Issue
- 12
- Pages
- 1535-1542
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2135275578
- Cited by
- 45
- References
- 20
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting insulin-like growth factor-1 to treat Alzheimer's disease. https://app.cochat.ai/papers/10.1517/14728222.11.12.1535
- The paper
- Torres-Aleman, I. (2007). Targeting insulin-like growth factor-1 to treat Alzheimer's disease. Expert Opinion on Therapeutic Targets. https://doi.org/10.1517/14728222.11.12.1535
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.